Chattem, INC D/B/A Opella
Healthcare related to nonprescription drugs and dietary supplements.
Based in NJ
🤖
AI Overview
With $730K in lobbying spend across 5 quarterly filings, Chattem, INC D/B/A Opella is an active lobbying client. Their lobbying covers 4 issue areas.
$730K
Total Spend
1
Years Active
1
Firms Hired
1
Lobbyists Deployed
4
Issues Lobbied
Spending Trend
View as table
| Year | Lobbying Spend |
|---|---|
| 2025 | $730K |
Issues Lobbied
Lobbying Firms
Lobbyists
What They Lobby About
These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Health Issues, Taxation, Trade, Consumer Issues
- •Healthcare policy for non-prescription drugs and dietary supplements, tax and trade.
- •Non-prescription drug issues. Monograph reauthorization. Rx to OTC switch. HSA/FSA.
- •Regulatory pathways for OTC drugs and dietary supplements, including OMUFA and Rx to OTC switch.
Related Analysis
Related Investigations
Big Pharma's $452M Lobbying Machine
How pharmaceutical companies spend hundreds of millions to influence health policy.
Healthcare's $3 Billion Bet
The healthcare industry's massive lobbying investment.
The 22,000% ROI
When lobbying spending yields outsized returns.
The 2025 Tariff Panic
As tariffs return, lobbying on trade surges.
Federal Lobbying Statistics 2025
The definitive stats — $37.7B total, industry breakdowns, and trends.
What Is Lobbying? A Complete Guide
How lobbying works, who does it, and why it matters.
Similar Clients
Explore More
Data Sources: Senate LDA Filings
Last updated: February 2026
This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.